Prevention of Venous Thromboembolism in Nonsurgical Patients ----- Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.

Slides:



Advertisements
Similar presentations
Evidence-Based Management of Anticoagulant Therapy
Advertisements

Hollie Shaner-McRae DNP RN FAAN
LHD Logo Venous Thromboembolism Reducing the Risk DATE.
Treatment of Acute Pulmonary Embolism
2012 CHEST Guideline Update VTE prophylaxis, DVT treatment, and Atrial Fibrillation LT Tabatha Welker, PharmD Pharmacy Resident, PHS Claremore Indian Hospital.
IN THE NAME OF GOD. Prevention of Venous Thromboembolism Dr.Shirali.
VTE in abdominal-pelvic surgery patients
Antithrombotic Therapy for Venous Thromboembolic Diseases
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
VTE Prophylaxis Alert to providers and nursing Go live June 24, 2014.
DVT Prophylaxis in Medical Patients Rog Kyle, MD MUSC 6/5/12.
Post OP Glucose Control For Cardiac Surgery The Society of Thoracic Surgeons Workforce guidelines (Lazar, 2009) recommended cardiac surgery patients, with.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
WHAT YOU NEED TO KNOW ABOUT BLOOD CLOTS VTE Venous Thromboembolism Toolkit for Health Professionals.
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
Thromboembolism IT training Presentation Midwifery update Marie Lewis.
What You Need to Know about Blood Clots. What You Need to Know About Blood Clots or Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Venous Thromboembolism
Risk assessment for VTE
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Cost-Consciousness Assignment Ollie Ross DSR 2. Adherence to ACP DVT prophylaxis guidelines Objective: Evaluate adherence to ACP DVT prophylaxis guidelines.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
Risk Assessment for VTE. Which of the following best describes you?
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
Quality and Patient Safety Council May 27, 2014 Presented By Susan M. Blackhurst BS, RN & Eric Jean BSN, RN, CCRN.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Shannon M. Bates, MDCM, MSc Ian A. Greer, MD, FMedSci, FCCP Saskia Middeldorp, MD, PhD David.
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Diagnosis of Deep Vein Thrombosis Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis, 9th.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis Frequency, Risk Factors, and Outcomes David R. Williamson, BPharm, MSc ; Martin.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
Outpatient DVT assessment & treatment Daniel Gilada.
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
The Primary and Secondary Prevention of Cardiovascular Disease
Venous Thromboembolism Prophylaxis for Medical Inpatients
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Evidence-Based Management of Anticoagulant Therapy
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Antithrombotic Therapy in Atrial Fibrillation
Antithrombotic Therapy in Peripheral Artery Disease
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
by Alex C. Spyropoulos, and James D. Douketis
Creating Clinical Practice Guidelines We Can Trust, Use, and Share
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Thrombophilia in pregnancy: Whom to screen, when to treat
Presentation transcript:

Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Guideline Team Expertise in: thrombosis, bleeding disorders, critical care, preventive medicine, methodology, cost effectiveness and two frontline physicians Susan R. Kahn MD, MSc Wendy Lim MD, MSc Andrew Dunn, MD Mary Cushman, MD Francesco Dentali, MD Elie A. Akl, MD, MPH, PhD Deborah J. Cook MD, MSc Alex A. Balekian, MD, MSHS Russell C. Klein, MD Hoang Le, MD, FCCP Sam Schulman, MD Mohammad Hassan Murad, MD, MPH Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Hospitalized Acutely Ill Medical Patients For acutely ill hospitalized medical patients at increased risk of thrombosis, we recommend anticoagulant thromboprophylaxis with low-molecular-weight heparin [LMWH], low-dose unfractionated heparin (LDUH) bid, LDUH tid, or fondaparinux (Grade 1B). Remarks: In choosing the specific anticoagulant drug to be used for pharmacoprophylaxis, choices should be based on patient preference, compliance, and ease of administration (eg, daily vs bid vs tid dosing), as well as on local factors affecting acquisition costs (eg, prices of various pharmacologic agents in individual hospital formularies). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Hospitalized Acutely Ill Medical Patients For acutely ill hospitalized medical patients at low risk of thrombosis, we recommend against the use of pharmacologic prophylaxis or mechanical prophylaxis (Grade 1B). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Hospitalized Acutely Ill Medical Patients For acutely ill hospitalized medical patients who are bleeding or at high risk for bleeding, we recommend against anticoagulant thromboprophylaxis (Grade 1B). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Hospitalized Acutely Ill Medical Patients For acutely ill hospitalized medical patients at increased risk of thrombosis who are bleeding or at high risk for major bleeding, we suggest the optimal use of mechanical thromboprophylaxis with graduated compression stockings (GCS) (Grade 2C) or intermittent pneumatic compression (IPC) (Grade 2C), rather than no mechanical thromboprophylaxis. When bleeding risk decreases, and if VTE risk persists, we suggest that pharmacologic thromboprophylaxis be substituted for mechanical thromboprophylaxis (Grade 2B). Remarks: Patients who are particularly averse to the potential for skin complications, cost, and need for clinical monitoring of GCS and IPC use are likely to decline mechanical prophylaxis. Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Hospitalized Acutely Ill Medical Patients In acutely ill hospitalized medical patients who receive an initial course of thromboprophylaxis, we suggest against extending the duration of thromboprophylaxis beyond the period of patient immobilization or acute hospital stay (Grade 2B). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Critically Ill Patients In critically ill patients, we suggest against routine ultrasound screening for DVT (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Critically Ill Patients For critically ill patients, we suggest using LMWH or LDUH thromboprophylaxis over no prophylaxis (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Critically Ill Patients For critically ill patients who are bleeding, or are at high risk for major bleeding, we suggest mechanical thromboprophylaxis with GCS (Grade 2C) or IPC (Grade 2C) until the bleeding risk decreases, rather than no mechanical thromboprophylaxis. When bleeding risk decreases, we suggest that pharmacologic thromboprophylaxis be substituted for mechanical thromboprophylaxis (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Patients With Cancer In outpatients with cancer who have no additional risk factors for VTE, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and recommend against the prophylactic use of vitamin K antagonists (Grade 1B). Remarks: Additional risk factors for venous thrombosis in cancer outpatients include previous venous thrombosis, immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide, and lenalidomide. Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Patients With Cancer In outpatients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic dose LMWH or LDUH over no prophylaxis (Grade 2B). Remarks: Additional risk factors for venous thrombosis in cancer outpatients include previous venous thrombosis, immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide, and lenalidomide. Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Patients With Cancer In outpatients with cancer and indwelling central venous catheters, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and suggest against the prophylactic use of vitamin K antagonists (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Chronically Immobilized Outpatients In chronically immobilized persons residing at home or at a nursing home, we suggest against the routine use of thromboprophylaxis (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Long-distance Travel For long-distance travelers at increased risk of VTE (including previous VTE, recent surgery or trauma, active malignancy, pregnancy, estrogen use, advanced age, limited mobility, severe obesity, or known thrombophilic disorder), we suggest frequent ambulation, calf muscle exercise, or sitting in an aisle seat if feasible (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Long-distance Travel For long-distance travelers at increased risk of VTE (including previous VTE, recent surgery or trauma, active malignancy, pregnancy, estrogen use, advanced age, limited mobility, severe obesity, or known thrombophilic disorder), we suggest use of properly fitted, below-knee GCS providing 15 to 30 mm Hg of pressure at the ankle during travel (Grade 2C). For all other long-distance travelers, we suggest against the use of GCS (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Long-Distance Travel For long-distance travelers, we suggest against the use of aspirin or anticoagulants to prevent VTE (Grade 2C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Persons With Asymptomatic Thrombophilia In persons with asymptomatic thrombophilia (ie, without a previous history of VTE), we recommend against the long-term daily use of mechanical or pharmacologic thromboprophylaxis to prevent VTE (Grade 1C). Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Thromboprophylaxis in these settings is described in the surgical chapter: –Trauma –Spinal cord injuries –Burn victims Thromboprophylaxis using aspirin: no statement was made due to sparse data in medical patients Other Nonsurgical Settings Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Acknowledgement of Support The ACCP appreciates the support of the following organizations for some part of the guideline development process: Bayer Schering Pharma AG National Heart, Lung, and Blood Institute ( Grant No.R13 HL104758) With educational grants from Bristol-Myers Squibb and Pfizer, Inc. Canyon Pharmaceuticals, and sanofi-aventis U.S. Although these organizations supported some portion of the development of the guidelines, they did not participate in any manner with the scope, panel selection, evidence review, development, manuscript writing, recommendation drafting or grading, voting, or review. Supporters did not see the guidelines until they were published. Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher

Endorsing Organizations This guideline has received the endorsement of the following organizations: American Association for Clinical Chemistry American College of Clinical Pharmacy American Society of Health-System Pharmacists American Society of Hematology International Society of Thrombosis and Hemostasis Copyright © 2016 American College of Chest Physicians. No part of this publication may be reproduced/used in any manner without permission from the publisher